HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews (5/07)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: In Inflammation, the Indication's the Thing, features profiles of Anthera Pharmaceuticals, Logical Therapeutics, Opsona Therapeutics and VLST Corp.. Plus these Start-Ups Across Health Care: Biodesy, Magenta Medical and NuLens.

You may also be interested in...

Logical Therapeutics Inc.

The gastrointestinal problems linked to NSAIDS are certainly no secret: the ability to mitigate them turned Vioxx into a blockbuster drug, that is, until it was pulled from the market because of cardiovascular problems. Now, Logical Therapeutics in-licensed rights to a pro-drug of naproxen that it thinks will have the GI-safety profile of Vioxx and the cardiovascular safety profile of naproxen.

Opsona Therapeutics Ltd.

Opsona Therapeutics is focusing on Toll-like receptors, which control the activity of regulatory T cells, signaling the presence of infection and triggering the inflammatory immune response. The company will identify key preclinical candidates (either in-house or licensed-in) and take them to development points of value before partnering. The Trinity College spin-out has struck its first two deals: with Wyeth Pharmaceuticals and with Phylogica.

VLST Corp.

VLST is developing a platform around the identification and understanding of the function of virulence factors, a set of proteins in viruses that down regulate the host's immune response, thereby conferring a survival advantage. Understanding this evolutionary process can lead to the identification of a group of clinically relevant cellular targets, as the predicate for the development of therapeutics.

Related Content

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts